research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
=== Packages === Tetra Classic is the name of the first, tetrahedral package, launched by Tetra Pak in 1952, with an aseptic version released in 1961 and still in use, mainly for portion-sized cream packages and children's juices. The Tetra Brik, a package in the shape of a rectangular cuboid, was launched in 1963 after a long and costly development process. An aseptic version, Tetra Brik Aseptic was launched in 1969. In terms of entities sold, it is the most popular of the Tetra Pak packages. The pillow-shaped Tetra Fino Aseptic was introduced in 1997, aiming to provide low cost and simplicity. Tetra Gemina Aseptic was introduced in 2007 as the "world’s first roll-fed gable top package with full aseptic performance". The Tetra Prisma Aseptic was launched in 1996. It has an octagonal shape with the aim of providing a more ergonomic experience. The Tetra Rex is a cuboid shaped package with a gable-top. It was launched in Sweden in 1966. Tetra Recart was launched in 2003 and is a package shaped as a rectangular cuboid that is meant to provide an alternative to previously canned foodstuffs such as vegetables, fruit and pet food. Tetra Top was launched in 1986 as a re-closable, rounded cuboid package with a plastic upper part, including opening and closure elements. The lid, molded in polyethylene in a single mold, makes it easy to open and reclose. Tetra Wedge Aseptic was developed to keep packaging material to a minimum while retaining a square surface underneath. It was introduced in 1997.
The Green Berets would become actively involved against the Iranian-backed Special Groups, TF-17 relied a good deal on the Green Berets mentoring teams with the ISOF, the Green Berets placed ODA's in outfits such as the INIS and the Iraqi commando brigade. The ODA's consisted of 20 men and became — during the course of 2007 — the key to coalition operations in provinces such as Dhi Ghar or Maysan, the teams ensured that operations in the Shia militant strongholds had an Iraqi face to them — something of great symbolic importance to the US relationship with the Iraqi government. Green Berets and Polish GROM conducted Operation Jackal against insurgents in Diwaniyah in 2007. During May and June 2007, many Shia arrest operations were conducted by the British SAS and TF-17s Green Berets and Iraqi commandos led to Muqtada al-Sadr to initially flee to Iran, and in August he declared a Mahdi Army ceasefire with the coalition.
Critics argue these programs are ineffective at preventing fatalities and advocate for alternatives such as helicopter patrols, acoustic tagging, and real-time social media tracking. While Western Australia implemented a cull in 2013, it was discontinued the following year following a recommendation from the state's Environmental Protection Authority. In April 2007, white sharks were given full protection within New Zealand waters 370 km (230 mi) from land, and from New Zealand-flagged vessels operating internationally. Violations carry penalties of up to a $250,000 fine and six months' imprisonment. In June 2018 the New Zealand Department of Conservation classified the white shark under the New Zealand Threat Classification System as "Nationally Endangered" due to its small, stable of between 250–1000 mature individuals. This classification carries the qualifiers "Data Poor", "Threatened Overseas", and "Conservation Dependent".
The half-lives of nuclei in the island of stability itself are unknown since none of the nuclides that would be "on the island" have been observed. Many physicists believe that the half-lives of these nuclei are relatively short, on the order of minutes or days. Some theoretical calculations indicate that their half-lives may be long, on the order of 100 years, or possibly as long as 109 years. The shell closure at N = 184 is predicted to result in longer partial half-lives for alpha decay and spontaneous fission. It is believed that the shell closure will result in higher fission barriers for nuclei around 298Fl, strongly hindering fission and perhaps resulting in fission half-lives 30 orders of magnitude greater than those of nuclei unaffected by the shell closure. For example, the neutron-deficient isotope 284Fl (with N = 170) undergoes fission with a half-life of 2.5 milliseconds, and is thought to be one of the most neutron-deficient nuclides with increased stability in the vicinity of the N = 184 shell closure. Beyond this point, some undiscovered isotopes are predicted to undergo fission with still shorter half-lives, limiting the existence and possible observation of superheavy nuclei far from the island of stability (namely for N < 170 as well as for Z > 120 and N > 184). These nuclei may undergo alpha decay or spontaneous fission in microseconds or less, with some fission half-lives estimated on the order of 10−20 seconds in the absence of fission barriers.
Sources: en.wikipedia.org
Shodex is the brand name of HPLC columns and is best known for polymer-based columns. The product range covers aqueous and organic Size Exclusion Chromatography columns for large (bio-)molecules, columns for the routine analysis of sugars and organic acids, and a variety of Reversed Phase and HILIC columns. Additionally they offer Ion Chromatography (IC) and Ion Exchange columns. Shodex HPLC Columns are manufactured in Japan by Resonac (formerly known as Showa Denko), one of the largest Japanese chemical companies and listed in the Nikkei 225 index. They produce around 260 different columns, most packed with polymer-based particles, and have been doing so since 1974. The portfolio includes standard analytical columns, semi-micro columns, and preparative columns. Also size exclusion chromatography calibration standards are available (Pullulan, Polystyrene, Polymethylmethacrylate) Shodex is distributed worldwide by the different sales offices and by a range of local distributors.
== L == Lac repressor – lactic acid autotroph – lagging strand – lambda phage – larva – leading strand – leaf – White blood cells – lichen – life form – life – light reactions – limbic system – limnology – Lineweaver-Burk diagram – lipase – lipid – liver – locus – long-term potentiation – Louis Pasteur – lung – Lynn Margulis – Lyon hypothesis – lysis – lysozyme – lytic cycle
A chromatography column is a device used in chromatography for the separation of chemical compounds. A chromatography column contains the stationary phase, allowing the mobile phase to pass through it.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.